Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study.

Opstal-van Winden AW, Krop EJ, Kåredal MH, Gast MC, Lindh CH, Jeppsson MC, Jönsson BA, Grobbee DE, Peeters PH, Beijnen JH, van Gils CH, Vermeulen RC.

BMC Cancer. 2011 Aug 26;11:381. doi: 10.1186/1471-2407-11-381.

2.

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.

Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH.

Oncol Rep. 2009 Jul;22(1):205-13.

PMID:
19513525
3.

Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).

Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH.

Clin Chem Lab Med. 2009;47(6):694-705. doi: 10.1515/CCLM.2009.151.

PMID:
19416081
4.

Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study.

van Winden AW, Gast MC, Beijnen JH, Rutgers EJ, Grobbee DE, Peeters PH, van Gils CH.

BMC Med Genomics. 2009 Jan 19;2:4. doi: 10.1186/1755-8794-2-4.

5.

Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.

Pietrowska M, Marczak L, Polanska J, Behrendt K, Nowicka E, Walaszczyk A, Chmura A, Deja R, Stobiecki M, Polanski A, Tarnawski R, Widlak P.

J Transl Med. 2009 Jul 13;7:60. doi: 10.1186/1479-5876-7-60.

6.

Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.

Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, Choi-Miura NH, Goggins M, Chan DW, Zhang Z.

Clin Chem. 2006 Jun;52(6):1045-53. Epub 2006 Mar 30.

7.

Early diagnostic protein biomarkers for breast cancer: how far have we come?

Opstal-van Winden AW, Vermeulen RC, Peeters PH, Beijnen JH, van Gils CH.

Breast Cancer Res Treat. 2012 Jul;134(1):1-12. doi: 10.1007/s10549-011-1907-2. Epub 2011 Dec 17. Review.

PMID:
22179926
8.

Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry.

Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW.

Clin Chem. 2005 Dec;51(12):2229-35. Epub 2005 Oct 13.

9.

Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

Opstal-van Winden AW, Beijnen JH, Loof A, van Heerde WL, Vermeulen R, Peeters PH, van Gils CH.

J Clin Lab Anal. 2012 Jan;26(1):1-9. doi: 10.1002/jcla.20492.

PMID:
24833528
10.

Detection and identification of potential biomarkers of breast cancer.

Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J, Zheng S, Li M, Wang J.

J Cancer Res Clin Oncol. 2010 Aug;136(8):1243-54. doi: 10.1007/s00432-010-0775-1. Epub 2010 Mar 17.

PMID:
20237941
11.

Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC.

Breast Cancer Res. 2014 Jun 16;16(3):R63. doi: 10.1186/bcr3676.

12.

Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer.

Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C.

Ann Surg Oncol. 2004 Oct;11(10):907-14. Epub 2004 Sep 20.

PMID:
15383419
13.

Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.

Yang J, Xiong X, Liu S, Zhu J, Luo M, Liu L, Zhao L, Qin Y, Song T, Huang C.

Proteomics. 2016 Mar;16(6):925-34. doi: 10.1002/pmic.201500321. Epub 2016 Feb 29.

PMID:
26705257
14.

The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.

Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, Deniz M, Cökmez A, Tarcan E.

Int J Med Sci. 2011 Feb 12;8(2):148-55.

15.

Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Zhao W, Li J, Zhang J, Gao P, Pei H, Wang L, Guo F, Yu J, Zheng S, Wang J.

Int J Mol Sci. 2015 Jun 4;16(6):12669-85. doi: 10.3390/ijms160612669.

16.

Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.

Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M.

Clin Chem Lab Med. 2009;47(6):713-23. doi: 10.1515/CCLM.2009.158.

PMID:
19426140
17.

Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma.

Liu C, Pan C, Wang H, Yong L.

Tumour Biol. 2011 Dec;32(6):1139-45. doi: 10.1007/s13277-011-0216-z. Epub 2011 Aug 9.

PMID:
21826475
18.

Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients.

Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, Feliberti EC, Perry RR, Drake RR.

J Am Coll Surg. 2009 May;208(5):970-8; discussion 978-80. doi: 10.1016/j.jamcollsurg.2008.12.024. Epub 2009 Mar 26.

PMID:
19476873
19.

Clinical proteomics in breast cancer: a review.

Gast MC, Schellens JH, Beijnen JH.

Breast Cancer Res Treat. 2009 Jul;116(1):17-29. doi: 10.1007/s10549-008-0263-3. Epub 2008 Dec 11. Review.

PMID:
19082706
20.

Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.

Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ.

Clin Cancer Res. 2005 Feb 1;11(3):1073-85.

Supplemental Content

Support Center